What is PCSK9 inhibitors?
The PCSK9 inhibitors are a new class of drugs that have been shown to dramatically lower LDL cholesterol levels. PCSK9 inhibitors are... Read More
Regeneron and Sanofi’s Praluent BLA Accepted for Priority Review by FDA
Posted on27 Jan 2015
Comments0
Clinical Program outcome highlight The BLA for Praluent contains data from more than 5,000 patients, including 10 Phase 3 ODYSSEY trials. Together... Read More